Enliven Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
ELVN$51.20-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · Additional Paid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income | Deficit | Equity | |
| Balance - January 1, 2024 | 41,292,027 | $41 | $400,172 | $141 | $(154,448) | $245,906 |
| Exercise of common stock options | 688,596 | 1 | 3,630 | — | — | 3,631 |
| Vesting of restricted stock units | 22,360 | — | — | — | — | — |
| Vesting of restricted stock awards and stock options | — | — | 273 | — | — | 273 |
| Issuance of common stock under the Employee Stock Purchase Plan | 49,722 | — | 651 | — | — | 651 |
| Issuance of common stock and pre-funded warrants in the Private Placement, net of issuance costs of $305 | 5,357,144 | 6 | 89,689 | — | — | 89,695 |
| Issuance of common stock under the Sales Agreement, net of issuance costs of $1,373 | 1,526,610 | 1 | 38,624 | — | — | 38,625 |
| Stock-based compensation | — | — | 20,174 | — | — | 20,174 |
| Net loss | — | — | — | — | (89,024) | (89,024) |
| Other comprehensive loss | — | — | — | (86) | — | (86) |
| Balance - December 31, 2024 | 48,936,459 | $49 | $553,213 | $55 | $(243,472) | $309,845 |
| Exercise of common stock options | 516,013 | — | 2,295 | — | — | 2,295 |
| Vesting of restricted stock units | 30,172 | — | — | — | — | — |
| Vesting of stock options | — | — | 67 | — | — | 67 |
| Issuance of common stock under the Employee Stock Purchase Plan | 36,414 | — | 620 | — | — | 620 |
| Issuance of common stock and pre-funded warrants in the Public Offering, net of issuance costs of $13,875 | 9,920,987 | 10 | 216,159 | — | — | 216,169 |
| Stock-based compensation | — | — | 34,019 | — | — | 34,019 |
| Net loss | — | — | — | — | (103,694) | (103,694) |
| Other comprehensive income | — | — | — | 279 | — | 279 |
| Balance - December 31, 2025 | 59,440,045 | $59 | $806,373 | $334 | $(347,166) | $459,600 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.